Neurodegeneration

InvestmentPitch Media Video Discusses FSD Pharma’s Submission of its Clinical Trial Application for Planned Phase-1 Trial for Lucid-MS, a Candidate for Treatment of MS

Retrieved on: 
Jeudi, janvier 19, 2023
Disease, News, PEA, Clinical trial, Caregiver, MS, IR, CSE, Degenerative disease, Quality of life, Inflammation, FSD, Honours degree, Patient, Canadian Securities Exchange, Multiple sclerosis, Research, Neurodegeneration, Pharmacy, Pharmaceutical industry

A Media Snippet accompanying this announcement is available by clicking on the image or link below:

Key Points: 
  • A Media Snippet accompanying this announcement is available by clicking on the image or link below:
    For more information, please view the InvestmentPitch Media video which provides additional information about this news and the company.
  • The video is available for viewing on “ InvestmentPitch ” and on “ YouTube ”.
  • If these links are not enabled, please visit www.InvestmentPitch.com and enter “FSD Pharma” in the search box.
  • Preclinical evidence also showed that Lucid-MS promotes functional recovery in experimental animal models of MS. Lucid-MS has demonstrated excellent results in several animal models.

KemPharm Partners with the Hypersomnia Foundation to Support Sleep Disorder Research and Advocacy

Retrieved on: 
Mercredi, janvier 18, 2023
Disease, Caregiver, MFA, CNS, Sleep disorder, IH, Safety, Knowledge, Idiopathic hypersomnia, Partnership, Central nervous system, KMPH, Therapy, Patient, Glycogen storage disease, Hypersomnia, Sleep, Neurodegeneration, Pharmaceutical industry

IH is a chronic neurologic disorder marked by significant detrimental effects on nighttime sleep as well as daytime sleepiness/wakefulness.

Key Points: 
  • IH is a chronic neurologic disorder marked by significant detrimental effects on nighttime sleep as well as daytime sleepiness/wakefulness.
  • KemPharm expects to enroll approximately 48 adult patients with IH in more than 30 centers in the United States.
  • “IH is a rare sleep disorder for which few treatment options exist.
  • “Support from sponsors like KemPharm are key to our efforts to advocate for and support those dealing with debilitating sleep disorders.”

AC Immune Partner Life Molecular Imaging Initiates Phase 3 Study of Tau PET Diagnostic PI-2620 for Alzheimer’s Disease

Retrieved on: 
Mercredi, janvier 18, 2023
Government budget balance, AAIC, Pathology, Safety, LMI, AD, Conference, Alzheimer's disease, Neurodegeneration, Medical imaging, Virtual

PI-2620 was discovered in collaboration between AC Immune and LMI and is developed under a strategic collaboration and exclusive licensing agreement with LMI.

Key Points: 
  • PI-2620 was discovered in collaboration between AC Immune and LMI and is developed under a strategic collaboration and exclusive licensing agreement with LMI.
  • Dr. Andrea Pfeifer, Chief Executive Officer of AC Immune SA, commented: “We are delighted to see LMI launching this pivotal Phase 3 trial of PI-2620, our next generation, potentially best-in-class Tau PET tracer.
  • The ability to detect and quantify aggregated Tau with enhanced sensitivity and specificity, will improve our diagnostic confidence and accelerate clinical development of therapeutic interventions.
  • ; One year longitudinal change of Tau accumulation on [18F]PI-2620 PET in Alzheimer spectrum; Virtual poster presentation; AAIC 2022

Seragon Announces RESTORIN®, the Most Advanced Anti-Aging Nutraceutical to Date

Retrieved on: 
Jeudi, janvier 19, 2023
Neurodegeneration, Cell, Ageing, Journal of the ACM, Longevity, DNA, Harvard University, Mayo Clinic, NAD, Sirtuin, Protein, Diabetes, Research, Cancer, Scripps Research, Science, Vaccine

IRVINE, Calif., Jan. 19, 2023 /PRNewswire/ -- Seragon Biosciences, Inc. today announced the launch of RESTORIN®, an advanced nutraceutical for healthy aging.

Key Points: 
  • IRVINE, Calif., Jan. 19, 2023 /PRNewswire/ -- Seragon Biosciences, Inc. today announced the launch of RESTORIN®, an advanced nutraceutical for healthy aging.
  • For decades, the intricate nature of aging has left scientists with many stones unturned in the field of aging intervention.
  • The latest research has pinpointed senolytics and NAD+ as key technologies to address this challenge.
  • "We've been able to develop advanced forms of these molecules and a series of complex combinations to combat aging, using the best science we have.

Seragon Announces RESTORIN®, the Most Advanced Anti-Aging Nutraceutical to Date

Retrieved on: 
Jeudi, janvier 19, 2023
Neurodegeneration, Cell, Ageing, Journal of the ACM, Longevity, DNA, Harvard University, Mayo Clinic, NAD, Sirtuin, Protein, Diabetes, Research, Cancer, Scripps Research, Science, Vaccine

IRVINE, Calif., Jan. 19, 2023 /PRNewswire/ -- Seragon Biosciences, Inc. today announced the launch of RESTORIN®, an advanced nutraceutical for healthy aging.

Key Points: 
  • IRVINE, Calif., Jan. 19, 2023 /PRNewswire/ -- Seragon Biosciences, Inc. today announced the launch of RESTORIN®, an advanced nutraceutical for healthy aging.
  • For decades, the intricate nature of aging has left scientists with many stones unturned in the field of aging intervention.
  • The latest research has pinpointed senolytics and NAD+ as key technologies to address this challenge.
  • "We've been able to develop advanced forms of these molecules and a series of complex combinations to combat aging, using the best science we have.

BREAKTHROUGH PRIZE OPENS PUBLIC NOMINATIONS FOR 2024 PRIZES IN FUNDAMENTAL PHYSICS, LIFE SCIENCES & MATHEMATICS

Retrieved on: 
Jeudi, janvier 19, 2023
Tao, Maxim Kontsevich, Breakthrough Prize in Life Sciences, ALLEA, Physics, Parkinson's disease, New Horizons, Titia de Lange, Committee, Kavli Institute for the Physics and Mathematics of the Universe, Social, Breakthrough Prize in Mathematics, Neurodegeneration, Breakthrough Prize, Knowledge, ResearchGate, Woman, Doctor of Philosophy, Research, SAN, Science and Technology Select Committee, Breakthrough Prize in Fundamental Physics, Life, Federalisation of the European Union, Selection Committee, Interaction, Pharmaceutical industry, Interior design, Mathematics, Science, Humanities

SAN FRANCISCO, Jan. 19, 2023 /PRNewswire/ -- The public nomination period for the 2024 Breakthrough Prizes in Fundamental Physics, Life Sciences and Mathematics is now open.

Key Points: 
  • SAN FRANCISCO, Jan. 19, 2023 /PRNewswire/ -- The public nomination period for the 2024 Breakthrough Prizes in Fundamental Physics, Life Sciences and Mathematics is now open.
  • For the 12th year, the Breakthrough Prize, recognized as the world's largest science prize, will honor top scientists, handing out three prizes in Life Sciences, one in Fundamental Physics and one in Mathematics.
  • ResearchGate members are encouraged to nominate their peers for the 2024 prizes in Fundamental Physics, Life Sciences, and Mathematics.
  • One 2024 Breakthrough Prize in Mathematics ($3 million) will be awarded to an individual who has made outstanding contributions to the field of mathematics.

BREAKTHROUGH PRIZE OPENS PUBLIC NOMINATIONS FOR 2024 PRIZES IN FUNDAMENTAL PHYSICS, LIFE SCIENCES & MATHEMATICS

Retrieved on: 
Jeudi, janvier 19, 2023
Tao, Maxim Kontsevich, Breakthrough Prize in Life Sciences, ALLEA, Physics, Parkinson's disease, New Horizons, Titia de Lange, Committee, Kavli Institute for the Physics and Mathematics of the Universe, Social, Breakthrough Prize in Mathematics, Neurodegeneration, Breakthrough Prize, Knowledge, ResearchGate, Woman, Doctor of Philosophy, Research, SAN, Science and Technology Select Committee, Breakthrough Prize in Fundamental Physics, Life, Federalisation of the European Union, Selection Committee, Interaction, Pharmaceutical industry, Interior design, Mathematics, Science, Humanities

SAN FRANCISCO, Jan. 19, 2023 /PRNewswire/ -- The public nomination period for the 2024 Breakthrough Prizes in Fundamental Physics, Life Sciences and Mathematics is now open.

Key Points: 
  • SAN FRANCISCO, Jan. 19, 2023 /PRNewswire/ -- The public nomination period for the 2024 Breakthrough Prizes in Fundamental Physics, Life Sciences and Mathematics is now open.
  • For the 12th year, the Breakthrough Prize, recognized as the world's largest science prize, will honor top scientists, handing out three prizes in Life Sciences, one in Fundamental Physics and one in Mathematics.
  • ResearchGate members are encouraged to nominate their peers for the 2024 prizes in Fundamental Physics, Life Sciences, and Mathematics.
  • One 2024 Breakthrough Prize in Mathematics ($3 million) will be awarded to an individual who has made outstanding contributions to the field of mathematics.

Halia Therapeutics Appoints Former Amgen Executive, Margit M. Janát-Amsbury, MD, Ph.D., as Chief Medical Officer

Retrieved on: 
Jeudi, janvier 19, 2023
Neurodegeneration, Sumitomo Dainippon Pharma, SALT, University, Therapy, Division, NLRP3, Inflammation, Amgen, Biological engineering, Medicinal chemistry, Albertus Magnus College, University of Washington Department of Bioengineering, Gynecologic Oncology (journal), Nanomedicine, Pharmaceutical industry, MD

"I am honored to join Halia Therapeutics and work alongside this accomplished multi-disciplinary team of scientists and innovators.

Key Points: 
  • "I am honored to join Halia Therapeutics and work alongside this accomplished multi-disciplinary team of scientists and innovators.
  • The company's unique approach of targeting the NLRP3 inflammasome to resolve chronic inflammation has enormous potential within multiple therapeutic areas.
  • Prior to joining Halia Therapeutics as Chief Medical Officer, Dr. Janát-Amsbury served as an Executive Medical Director in Early Oncology Development at Amgen and was also the Product Team Lead for Amgen's prostate portfolio.
  • Before joining Amgen, she oversaw the development of multiple small molecules at Tolero Pharmaceuticals, which Sumitomo Dainippon Pharma acquired in 2017.

National Institute on Aging (NIA) awards $21M grant to support key phase 2b study of EIP Pharma's neflamapimod in dementia with Lewy bodies

Retrieved on: 
Mercredi, janvier 18, 2023
Disease, Attention, Brain, EEG, University, Caregiver, Lewy body, Even and odd functions, Biomarker, MD, Timed Up and Go test, DLB, Patient, NIA, Dementia, Alzheimer's disease, Neurodegeneration, NIH, Cognition, Pharmaceutical industry

The outcome of this phase 2b study could allow us to confirm the positive findings from our phase 2a study and definitively demonstrate the potential for neflamapimod to treat patients suffering from the second most common dementia, DLB.

Key Points: 
  • The outcome of this phase 2b study could allow us to confirm the positive findings from our phase 2a study and definitively demonstrate the potential for neflamapimod to treat patients suffering from the second most common dementia, DLB.
  • Therefore, it is with a heightened sense of responsibility and urgency that we look forward to moving the study forward with the phase 2b study commencing within the next few months".
  • Dr James Galvin from the University of Miami, co-principal investigator for the study, commented "DLB is the second most common neurodegenerative dementia, after Alzheimer's disease.
  • The NIA grant will fund a study that will be instrumental in fully understanding whether neflamapimod has the potential to become an important treatment for patients with DLB".

APRINOIA Therapeutics and ROSS Acquisition Corp II Announce Business Combination Agreement to Create Publicly Listed Company Focused on Neurodegenerative Diseases

Retrieved on: 
Mercredi, janvier 18, 2023
PET, PSP, ROSS, CNS, Therapy, Frontotemporal dementia, Acquisition, Alzheimer's disease, Neurodegeneration, Business, Pub, Combination, Parkinson's disease, Research, FTD, Physician, Alpha-synuclein, MSA, White & Case, Corticobasal degeneration, Multiple system atrophy, Business architecture, FDA, Cooley LLP, Tauopathy, NYSE, AD, Biogen, LLP, Webcast, Dementia, TDP43, Commerce, RMB, Patient, Central nervous system, Antibody, Movement disorders, Bristol Myers Squibb, Pharmaceutical industry, Security (finance), Medical imaging, Fine chemical, Financial adviser

PALM BEACH, Fla. and CAMBRIDGE, Mass., Jan. 18, 2023 /PRNewswire/ -- APRINOIA Therapeutics Inc. ("APRINOIA"), a clinical-stage biotechnology company focused on neurodegenerative diseases such as Alzheimer's Disease ("AD") and Progressive Supranuclear Palsy ("PSP"), and Ross Acquisition Corp II (NYSE: ROSS, ROSS.U, ROSS WS) ("ROSS"), a special purpose acquisition company founded by former Commerce Secretary Wilbur Ross, today announced that they have entered into a definitive agreement (the "Business Combination Agreement") for a business combination (the "Business Combination"). 

Key Points: 
  • APRINOIA and ROSS Acquisition Corp II: Business Combination Agreement Create Public Co., Neurodegenerative Target
    ROSS and APRINOIA are combining at an implied fully diluted transaction equity value of US$280 million for APRINOIA.
  • ROSS has entered into the Business Combination Agreement with APRINOIA, pursuant to which APRINOIA and ROSS will each become a wholly owned subsidiary of the combined company, APRINOIA Therapeutics Holdings Limited, a newly formed entity ("PubCo").
  • APRINOIA and Ross Acquisition Corp II will be hosting an investor call and slide presentation at 4:30 pm ET on Wednesday, January 18, 2023.
  • White & Case LLP acted as legal advisor to ROSS in connection with the proposed Business Combination.